Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

21.70USD
15 Aug 2018
Change (% chg)

$-0.77 (-3.43%)
Prev Close
$22.47
Open
$22.43
Day's High
$22.81
Day's Low
$21.48
Volume
605,845
Avg. Vol
726,444
52-wk High
$27.32
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA
Monday, 21 May 2018 

May 21 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION.IMMUNOMEDICS INC - FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC.  Full Article

Immunomedics Reports Q3 Loss Per Share $0.21
Wednesday, 9 May 2018 

May 9 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.21.Q3 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $500,000 VERSUS $1.3 MILLION.Q3 REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE.IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Immunomedics announces Q2 fiscal 2017 results and clinical program developments
Thursday, 9 Feb 2017 

Immunomedics Inc : Immunomedics announces second quarter fiscal 2017 results and clinical program developments . Immunomedics Inc says total costs and expenses for quarter ended December 31, 2016 were $15.7 million, compared to $16.4 million for same quarter in fiscal 2016 . Q2 loss per share $0.23 .Q2 revenue fell 43 percent to $400,000.  Full Article

Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers
Monday, 12 Dec 2016 

Immunomedics Inc : Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers . Completing enrollment of 100 TNBC patients into ongoing phase 2 clinical trial of IMMU-132 by year-end 2016 . Immunomedics - submitting a biological license application to FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017 .Immunomedics - presenting interim results of phase 2 clinical trials for patients with urothelial cancer at a symposium on genitourinary cancers to be held in early 2017.  Full Article

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION